This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will TherapeuticsMD (TXMD) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: TherapeuticsMD (TXMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in TherapeuticsMD (TXMD) Stock?
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 31.58% and 200.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -5.56% and 19.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: TherapeuticsMD (TXMD) Q2 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD Enters Agreement to Market Drugs Outside US
by Zacks Equity Research
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.88% and -41.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
Earnings Preview: TherapeuticsMD (TXMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD (TXMD) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Options Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock
by Zacks Equity Research
Investors in TherapeuticsMD (TXMD) need to pay close attention to the stock based on moves in the options market lately.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
by Zacks Equity Research
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.